PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 2013116
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 2013116
Diabetes Care Devices Market size was valued at US$ 65,460.82 Million in 2025, expanding at a CAGR of 6.57% from 2026 to 2033.
Diabetes care devices are medical tools that aid individuals in monitoring and managing their blood sugar levels effectively in everyday life. These devices include blood glucose meters for regular testing, continuous glucose monitoring systems that track sugar levels throughout the day, and insulin delivery devices such as pens and pumps. They enable patients to understand their condition better and take timely actions like adjusting diet, medication, or insulin intake. These tools are designed to be user-friendly, making it easier for both patients and healthcare providers to manage diabetes more accurately. Globally, this market is steadily growing due to the rising number of diabetes cases and increasing awareness about regular monitoring. According to the World Health Organization, over 422 million people worldwide are living with diabetes, and the number continues to rise, especially in developing countries. This growing patient base naturally increases the need for reliable monitoring and treatment devices. Governments are also actively supporting various diabetes management programs. For example, India's Ministry of Health and Family Welfare runs programs like NP-NCD, which promote early diagnosis and regular monitoring. Such initiatives encourage the use of glucose monitoring devices at both hospital and home levels.
Diabetes Care Devices Market- Market Dynamics
Increasing Focus on Early Diagnosis and Preventive Healthcare
The increasing attention toward early detection and preventive healthcare is significantly contributing to the expansion of this market. As awareness increases, more individuals are opting for routine screening and regular monitoring, even before severe symptoms appear. This shift encourages the use of glucose monitoring devices at an early stage, helping in better disease control and reducing long-term complications. Healthcare providers and public health bodies are also promoting timely testing and lifestyle management, which further increases the need for easy-to-use monitoring tools. On the company side, Dexcom reported continued growth in users of its CGM systems, reflecting higher adoption for proactive care. Likewise, Roche has highlighted strong demand for its Accu-Chek glucose monitoring solutions, widely used for daily testing and preventive care, too. The growing inclination toward proactive health management and routine health check-ups is consistently driving higher adoption of these devices.
The Global Diabetes Care Devices Market is segmented on the basis of Diabetes, Device, Distribution Channel, Technology, End-Use, and Region.
Under diabetes segmentation, the Type 2 diabetes segment is set to maintain prominence in the market, mainly because this type of diabetes represents the majority of diagnosed cases globally and is closely linked with lifestyle factors, aging populations, and changing dietary habits. As awareness increases, more individuals with Type 2 diabetes are using regular glucose monitoring devices to manage their condition effectively. Governments and healthcare systems are also encouraging early screening and continuous monitoring to prevent complications. From an industry perspective, Abbott Laboratories has reported strong global adoption of its Freestyle Libre continuous glucose monitoring system, which is widely used by people with Type 2 diabetes for convenient and real-time tracking. The high occurrence of this diabetes, combined with growing preventive care and advanced monitoring technologies, supports its position in this market.
As per the technology category, minimally invasive anticipated to play a central role in the market because it offers a practical balance between comfort, accuracy, and continuous monitoring. These systems, commonly known as continuous glucose monitoring (CGM) devices, reduce the need for frequent finger-prick tests while providing real-time glucose readings through small wearable sensors. This makes them easier for daily use and suitable for long-term diabetes management. They also connect with smartphones and digital health platforms, improving convenience and patient engagement. A strong example is Dexcom. According to its official financial results, Dexcom reported total revenue of $4.662 billion for fiscal year 2025, reflecting steady growth, with strong performance driven primarily by its sensor-based CGM systems. This projects the strength of this technology.
Diabetes Care Devices Market- Geographical Insights
Geographical perspective in this market indicates that the Asia-Pacific region is likely to experience notable growth, largely driven by the fast-growing number of people living with diabetes and improving healthcare attention across countries. As highlighted by the International Diabetes Federation, South-East Asia alone has over 100 million adults affected, and this figure is expected to increase significantly in the coming decades, creating a strong need for regular monitoring and effective disease management. Governments in the region are taking proactive steps by promoting early screening, awareness campaigns, and better access to healthcare services, particularly in developing economies. At the same time, companies such as Roche and Abbott Laboratories are expanding their presence with affordable and digitally enabled devices, including continuous glucose monitoring solutions. The presence of a large number of undiagnosed cases further strengthens the demand for advanced diagnostic tools.
Focusing on India, the country stands out as a major contributor within the region due to its large patient base and increasing awareness about diabetes care. Data from IDF also indicates that it has nearly 90 million adults living with diabetes, underlining the need for consistent monitoring solutions. The Ministry of Health and Family Welfare is actively supporting early detection and management through national health programs focused on non-communicable diseases. Meanwhile, companies are introducing budget-friendly and user-friendly devices, such as portable glucose monitors and connected digital tools, to meet the needs of a diverse population. Inclusive, improving awareness, better healthcare infrastructure, and a growing focus on preventive care are steadily encouraging the adoption of diabetes care devices across the region.
Across other regions, North America is also expected to witness meaningful growth, supported by a high disease burden and strong healthcare infrastructure. According to the Centers for Disease Control and Prevention, around 40.1 million people in the United States are living with diabetes, representing nearly 12% of the population. Additionally, the region accounts for one of the highest healthcare expenditures on diabetes globally, highlighting strong spending capacity and access to advanced devices. Government initiatives, such as awareness programs and funding for prevention and management, further encourage early diagnosis and continuous monitoring. At the same time, leading companies like Dexcom and Tandem Diabetes Care are continuously introducing innovative and connected devices, including real-time monitoring systems and automated insulin delivery solutions. The region's combination of high patient awareness, supportive policies, and a strong innovation ecosystem is steadily driving the adoption of diabetes care devices.
Diabetes Care Devices Market- Country Insights
Japan represents a well-established and steadily progressing market for diabetes care devices, supported by its aging population and increasing number of diabetes cases. According to the Ministry of Health, Labour and Welfare, a considerable share of the population is either living with diabetes or at high risk, creating a consistent need for monitoring and management solutions. The government promotes early detection and long-term care through regular health check-ups, screening programs, and awareness initiatives, encouraging timely diagnosis and treatment.
From an industry perspective, companies such as Terumo Corporation and Roche are offering advanced and dependable solutions, including glucose monitoring systems and insulin delivery devices. Japan's strong focus on innovation has also led to the development of compact and easy-to-use technologies. Overall, the country's supportive healthcare system, high awareness, and continuous advancements are driving steady adoption of devices.
The Diabetes Care Devices market is shaped by a mix of global leaders and regional players, making it highly competitive and innovation-driven. Companies such as Medtronic, Abbott Laboratories, Dexcom, and Insulet Corporation actively compete through advanced product offerings and patient-friendly technologies. Devices are distributed through hospitals, pharmacies, online platforms, and direct-to-consumer channels. Competition mainly revolves around accuracy, ease of use, connectivity features, pricing, and brand reliability, as companies aim to simplify everyday diabetes management.
To strengthen their position, companies focus on continuous innovation, partnerships, and expanding digital ecosystems. For example, Abbott entered a global partnership with Medtronic to combine its FreeStyle Libre CGM technology with Medtronic's insulin delivery systems. The goal is to create a more connected and automated diabetes care solution worldwide. Similarly, Insulet Corporation also expanded its Omnipod 5 system with multi-sensor compatibility and wider availability, improving flexibility for users. Overall, the market is steadily moving toward more connected, automated, and patient-focused solutions, driving ongoing innovation and collaboration among leading companies.
In January 2026, Abbott partnered with Withings to integrate its Lingo over-the-counter continuous glucose monitoring (CGM) technology into Withings' digital health ecosystem. This collaboration aims to expand glucose tracking access to millions of users for better metabolic health monitoring. This partnership broadens consumer access, promotes preventive health monitoring, and strengthens digital ecosystem integration for more accessible, data-driven metabolic health management.
In December 2025, Medtronic launched an insulin delivery system integrated with Abbott-developed continuous glucose monitoring (CGM) sensors. This marked the company's first integration with an external CGM technology, improving automated diabetes management solution. This integration enhances treatment efficiency, expands device compatibility, and supports more personalized, automated diabetes management for improved patient outcomes globally.